Valuation: Penumbra, Inc.

Capitalization 9.56B 9.08B 8.44B 7.52B 13.45B 810B 14.85B 104B 38.83B 332B 35.9B 35.11B 1,435B P/E ratio 2024 *
581x
P/E ratio 2025 * 66.3x
Enterprise value 9.25B 8.79B 8.17B 7.28B 13.02B 784B 14.38B 101B 37.59B 322B 34.75B 33.99B 1,389B EV / Sales 2024 *
7.77x
EV / Sales 2025 * 6.71x
Free-Float
96.13%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.57%
1 week+2.02%
Current month+2.03%
1 month+8.53%
3 months+22.97%
6 months+30.50%
Current year-0.98%
More quotes
1 week
241.91
Extreme 241.91
250.63
1 month
228.90
Extreme 228.9
250.95
Current year
148.00
Extreme 148
277.34
1 year
148.00
Extreme 148
277.34
3 years
114.87
Extreme 114.865
348.67
5 years
114.87
Extreme 114.865
348.67
10 years
35.32
Extreme 35.315
348.67
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2004-06-20
Director of Finance/CFO 52 2019-12-01
Chief Operating Officer - 2020-12-31
Manager TitleAgeSince
Chairman 62 2014-12-31
Chairman 62 2004-12-31
Director/Board Member 82 2008-01-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+1.57%+2.02%+8.99%+4.62%9.56B
-0.01%+0.01%+87.95%+102.74%12.57B
-1.42%+0.48%+69.39%-38.00%9.19B
+1.74%+7.04%+47.37%+80.66%5.07B
-0.45%+0.02%-2.35%+12.70%4.87B
-0.09%-1.79%+1.19%-1.50%4.7B
+1.63%+1.88%-24.59%-54.39%4.26B
-4.20%+48.45%+125.02%-64.38%3.16B
+1.26%+2.29%-16.84%-32.80%3.06B
-2.52%-2.11%-33.84%-57.47%1.52B
Average -0.25%+6.14%+26.23%-4.78% 5.8B
Weighted average by Cap. +0.03%+3.93%+38.84%+14.26%
See all sector performances

Financials

2024 *2025 *
Net sales 1.19B 1.13B 1.05B 936M 1.68B 101B 1.85B 13.01B 4.84B 41.37B 4.47B 4.37B 179B 1.36B 1.29B 1.2B 1.07B 1.92B 115B 2.12B 14.89B 5.53B 47.35B 5.12B 5.01B 205B
Net income 16.04M 15.23M 14.16M 12.61M 22.57M 1.36B 24.91M 175M 65.14M 557M 60.23M 58.91M 2.41B 146M 139M 129M 115M 206M 12.38B 227M 1.6B 593M 5.08B 549M 537M 21.94B
Net Debt -306M -291M -270M -241M -431M -25.93B -476M -3.35B -1.24B -10.64B -1.15B -1.12B -45.97B -414M -393M -366M -326M -583M -35.08B -643M -4.53B -1.68B -14.39B -1.56B -1.52B -62.18B
More financial data * Estimated data
Logo Penumbra, Inc.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Employees
4,200
More about the company
Date Price Change Volume
24-12-04 249.08 $ +1.57% 233,870
24-12-03 245.24 $ +0.16% 281,939
24-12-02 244.84 $ +0.29% 224,078
24-11-29 244.12 $ -0.01% 114,677
24-11-27 244.15 $ -1.93% 271,479

Delayed Quote Nyse, December 04, 2024 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart PENUMBRA-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
249.08USD
Average target price
241.07USD
Spread / Average Target
-3.22%
Consensus

Quarterly revenue - Rate of surprise